Trials / Recruiting
RecruitingNCT07116746
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
A Phase 2, Multicenter, Open-label, Efficacy and Safety Study of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Arthrosi Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AR882 75 mg | Solid Oral Capsule |
| DRUG | XOI Low Dose | Solid Oral Tablet |
| DRUG | XOI High Dose | Solid Oral Tablet |
Timeline
- Start date
- 2025-12-03
- Primary completion
- 2026-07-01
- Completion
- 2027-01-01
- First posted
- 2025-08-12
- Last updated
- 2026-03-02
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07116746. Inclusion in this directory is not an endorsement.